| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3189810 | Annales de Dermatologie et de Vénéréologie | 2007 | 5 Pages |
Abstract
These global response levels confirm the place of bexarotene in the treatment of folliculotropic lymphoma. Combined therapy appears to be warranted due to the difficulty in maintaining optimal dosages of the drug because of the frequency of adverse effects. Preventive therapy for the hypothyroidism seen in practically all cases should prevent adverse effects of the drug on sexual function.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
C. Drugeon, I. Charlat, S. Boulinguez, R. Viraben,